WO2014163338A1 - 피부투과가 개선된 외용제 조성물 - Google Patents
피부투과가 개선된 외용제 조성물 Download PDFInfo
- Publication number
- WO2014163338A1 WO2014163338A1 PCT/KR2014/002676 KR2014002676W WO2014163338A1 WO 2014163338 A1 WO2014163338 A1 WO 2014163338A1 KR 2014002676 W KR2014002676 W KR 2014002676W WO 2014163338 A1 WO2014163338 A1 WO 2014163338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- acid
- sodium
- external
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates to a composition for external application for skin, comprising tranexamic acid or a salt thereof and a percutaneous absorption accelerator, thereby significantly improving percutaneous permeability and improving usability, skin irritation and storage stability.
- Tranexamic acid is generally used as a hemostatic agent when taken, and as an ointment, an antiallergic or anti-inflammatory agent when applied, and is used in combination with 0TC drugs as well as medical drugs. In addition, it is effective in pigmentation such as blemishes, and is also used for pigmentation treatment and whitening applications.
- Korean Patent Registration No. 1087602 discloses a feeling of stickiness or stiffness when applying a low viscosity liquid composition containing tranexamic acid to the skin, especially when the tranexamic acid exceeds 0.5% by mass.
- domestic patent registration No. 1159574 has a very high crystallinity of tranexamic acid, so that crystals may precipitate during evaporation and drying in a skin external preparation containing tranexamic acid. Pointed out.
- Japanese Patent Application Laid-Open No. 2010-229100 points out a problem that the skin permeability is very low when applying tranexamic acid to the skin.
- tranexamic acid As an active ingredient, and in the case of commercially available commercial products, in the transdermal permeation experiment, tranexamic acid penetrated human skin at all. It was found that not (see Experimental Example 1 in the present specification).
- the present invention has developed an external preparation composition in which tranexamic acid penetrates the skin without skin irritation, and has excellent usability and does not precipitate out the tranexamic acid crystals during storage, thereby completing the present invention.
- one object of the present invention is to provide an external composition for skin comprising tranexamic acid or a salt thereof, and a transdermal absorption accelerator.
- the present invention provides a stable skin external preparation composition which transmits the skin at a high rate without causing skin irritation and has excellent feeling of use, and does not precipitate storage tranexamic acid crystals, and therefore, various medicines using tranexamic acid as an active ingredient And cosmetics.
- Example 1 shows the results of measuring the transdermal permeability (3 ⁇ 4) with time of Examples 4, 8, 10-15 formulations and Comparative Example 1 formulations.
- Figure 2 shows the stability of the formulation of Example 4 under a microscope.
- Figure 3 shows the melanin index (Skin melasma index) evaluation results of the negative control (vehicle), Examples 4, 8, 10-12 formulation.
- the present invention relates to tranexamic acid or a salt thereof, and
- the present invention relates to an external composition for skin containing a percutaneous absorption accelerator.
- the present invention relates to a method for enhancing skin absorption of tranexamic acid or a salt thereof, comprising applying to the skin a composition comprising tranexamic acid or a salt thereof and a transdermal absorption accelerator.
- TA Tranexamic acid
- tranexamic acid is an antiplasmin agent and has anti-coagulation, anti-allergic and anti-inflammatory effects, and is known to have pigmentation inhibitory effects such as blemishes, blemishes, freckles, skin tone, and skin texture improvement.
- tranexamic acid may be used in the form of a pharmaceutically or cosmetically acceptable salt, and the salt includes a salt derived from an inorganic acid, an organic acid, or a base.
- the salt may be used as an alkali metal salt such as gallium salt or magnesium salt, an inorganic acid salt such as alkaline earth metal salt or sulfate salt.
- tranexamic acid or a salt thereof may be purchased and used by a method known or known in the art.
- the present invention can be applied not only to the tranexamic acid or salts thereof, but also to derivatives thereof, and known derivatives of tranexamic acid include dimers of tranexamic acid [trans-4- (trans-4-aminomethylcyclonucleocarbonyl) ) Aminomethylcyclonucleic Acid Carboxylate Hydrochloride], Esters of Tranexamic Acid and Hydroxyquinone (Trans-4-aminomethylcyclonucleic Acid
- Carboxylate-4'-hydroxyphenyl ester ester of tranexamic acid and gentisic acid [2- (trans- 4-aminomethylcyclonucleocarbonyloxy) -5-hydroxybenzoic acid and its salts], tra Amides of nexamic acid [trans-4-aminomethylcyclonucleic acid carboxylate methylamide and salts thereof, trans-4-acetylaminomethylcyclonucleic acid carboxylic acid and salts thereof, trans-4— (P-methoxybenzoyl) aminomethyl Cyclonucleic acid carboxylic acid and its salt trans-4-guanidinomethylcyclonucleic acid carboxylic acid and its salt, etc.] etc. can be illustrated.
- tranexamic acid or a salt thereof may be included in an amount of 0.01 to 10% by weight based on the total composition. If less than the above range If a clear effect cannot be expected, transdermal permeability may be increased when the above range is exceeded, but solubility of the composition base may be lowered, thereby lowering stability or dispersion of the main component.
- the tranexamic acid by blending the tranexamic acid with a transdermal absorption accelerator, it provides a skin external composition for remarkably improved the skin absorption of tranexamic acid.
- the present invention is a transexamic acid-containing skin external preparation having a transdermal transmittance of at least 10% after 24 hours of application to the skin, a transdermal transmittance of at least 15% after 48 hours, and a transdermal transmittance of at least 25% after 72 hours.
- a transexamic acid-containing skin external preparation having a transdermal transmittance of at least 10% after 24 hours of application to the skin, a transdermal transmittance of at least 15% after 48 hours, and a transdermal transmittance of at least 25% after 72 hours.
- composition of the present invention including 1 to 10% by weight, more preferably 2 to 5% by weight of the percutaneous absorption accelerator based on the total composition, it can exhibit properties excellent skin irritation and ease of use. If it is less than the above range it may be difficult to achieve the intended transdermal absorption, if it exceeds the above range may irritate the skin and the feeling of use may be reduced.
- the percutaneous absorption accelerator which is applied to the present invention, is not limited thereto, but is not limited thereto, sorbitol, isopropyl myristate, concentrated glycerin, propylene glycol monolaurate polysorbate, butylene glycol, diethylene glycol monoethyl ester glyceryl Monorate, polyglyceryl-6 dioleate, oleylpolysyl-6 glyceride capriol capryl polyoxyglyceride, linoyl polyoxyglyceride triglyceride, propylene glycol dicaprylol capparate, triglysaride capryl, Caprylglycerol, polyoxyethylene capric, and the like.
- the sorbbi is one or more selected from the group consisting of isopropyl myristate, concentrated glycerin, propylene glycol monolarate and polysorbate.
- blended with the composition applied to skin or mucous membrane can be mix
- components for example, surfactants, pH adjusters, pigments, flavorings, preservatives, fungicides, thickeners, antioxidants, metal ion sequestrants, fresheners, deodorants, various additives in addition to the moisturizer, ultraviolet light Absorbers, ultraviolet scatterers, vitamins, plant extracts, skin astringents, anti-inflammatory agents, whitening agents, cell activators, vasodilators, blood circulation promoters, and skin function enhancers.
- a known base or carrier may be used depending on the formulation.
- the topical skin composition of the present invention further comprises at least one selected from the group consisting of a surfactant, a pH adjuster and a thickener, thereby further enhancing the effect of enhancing the feeling and stability and minimizing skin irritation.
- the surfactant may include 1 to 10% by weight, more preferably 3 to 6% by weight based on the total composition, to lower the surface tension can be easily mixed with the water phase and oil phase.
- surfactant examples include, but are not limited to, higher fatty acid soaps, alkyl sulfate ester salts, polyoxyethylene alkyl ether sulfates, alkyl ether phosphate ester salts, N-acylamino acid salts, acyl N-methyltaurine salts, and the like.
- the pH adjusting agent When the pH adjusting agent is included, 0.01 to 2% by weight, more preferably 0.1 to 0.5% by weight based on the total composition, it is possible to maintain the stability of the external composition.
- pH regulators include sodium hydroxide, boric acid, citric acid, alkinoamide, triethanolamine, acetic acid, sodium bicarbonate, phosphoric acid, aqueous ammonia, sodium sulfite, sodium nucleate metaphosphate, gluconodeltalacson, adipic acid, sodium dephosphate Etc. may be illustrated, but is not limited thereto.
- an appropriate viscosity can be given, including 0.01 to 3 weight 3 ⁇ 4 » more preferably 0.1 to 1.5% by weight, based on the total composition.
- metal ion sequestrant examples include, but are not limited to, sodium salt of ethylenediamine tetraacetic acid, phosphoric acid, citric acid, and the like.
- preservatives may be exemplified by, for example, ethyl paraoxybenzoate, salicylic acid, and sorbic acid.
- the formulation is a paste, cream or gel
- animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc or zinc oxide may be used as the carrier component. It may be.
- the formulation is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be used, especially in the case of a spray, additionally chloroflutohydrocarbon, propane / butane or dimethyl.
- Propellants such as ethers.
- a solvent, solubilizer or emulsion may be used as the carrier component, for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 Butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid ester.
- the dosage form is a suspension
- water, ethane or liquid diluents such as propylene glycol
- suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cells Rhodes, aluminum meta hydroxide, bentonite, agar or tracant may be used.
- the external preparation composition for skin of the present invention can be applied directly to the skin or sprayed according to its form.
- the amount of the composition and the number of times of daily use can be appropriately determined according to the age, sex, use, and degree of symptoms of the user. Although set, for example, an appropriate amount of the composition can be applied to the skin at a frequency of 5 or 6 cycles / day from once / day.
- the external preparation composition for skin of the present invention may be applied to various pharmaceutical compositions or cosmetic compositions using as the active ingredient of tranexamic acid or a salt thereof.
- composition When used as a pharmaceutical composition, it can be used as an anti-plasmin anti-unging agent, anti-allergic agent, anti-inflammatory or pigmentation treatment, and when used as a cosmetic composition, it is useful for improving blemishes, blemishes, freckles, skin tone or skin texture, and whitening. It can be used as a cosmetic composition.
- the present invention relates to a pharmaceutical composition for external use, including the tranexamic acid or a salt thereof, and a transdermal absorption accelerator.
- the external pharmaceutical composition herein includes drugs and quasi-drugs for external application.
- the form of such external pharmaceutical composition is not particularly limited as long as it is applicable to skin or mucous membranes, and examples thereof include any form such as an aqueous solution, a solubilizing system, an emulsifying system, a powder dispersion system, and a water / oil two-layer system. have. Specifically, liquids, emulsions, lotions, coating agents, emulsions, suspensions, creams, ointments and the like can be exemplified.
- whitening ingredients such as pantothenic acid or salts thereof, hydroquinones glucosamines, hinokithiols, azelaic acid or salts thereof, Tocopheryls, pyridoxines or salts thereof, ubiquinones, carotenes, flavones, isoflavones, flavanones, catechins, flavonols, glycilates, kojic acid or its salts, glutathic silver or its salts Salts and other natural extracts known to whitening activity may be exemplified, but are not limited thereto.
- the present invention relates to a cosmetic composition
- a cosmetic composition comprising the tranexamic acid or a salt thereof, and a transdermal absorption accelerator.
- the cosmetic composition according to the present invention comprises the tranexamic acid or a salt thereof as an active ingredient. It is characterized by blemish, blemish, freckles, dermatology, skin texture, inflammatory hyperpigmentation and whitening effect.
- the cosmetic composition according to the present invention may contain the Tranexamic acid or a salt thereof in an amount of 0.01 to 10 weight 3 ⁇ 4> with respect to the total amount of the composition. If it is less than the above range can not expect a distinct effect, if it exceeds the above range may be increased transdermal permeability, but the solubility of the composition base is lowered, the stability or dispersion of the main component may be lowered.
- the composition according to the invention may be formulated in the form of a cosmetic composition in one embodiment of the invention, such cosmetic composition may for example be a cosmetic. In this case, the cosmetic composition according to the present invention contains a cosmetically or dermatologically acceptable medium or base.
- compositions suitable for topical application for example emulsions, suspensions, microemulsions, microcapsules, microgranulocytes or ionic (liposomes) obtained by dispersing an oil phase in solution, gel, solid, pasty anhydride, water phase.
- nonionic vesicle dispersants or in the form of creams, skins, lotions, powders, ointments, sprays or cone sticks.
- Idol compositions can be prepared according to conventional methods in the art.
- the composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
- the cosmetic composition according to the present invention comprises a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softener, an antioxidant, a suspending agent, a stabilizer, a blowing agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier, Cosmetics or skin, such as layering agents, metal silver sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives such as lipid vesicles or any other ingredients commonly used in cosmetics It may contain adjuvants commonly used in the scientific field. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.
- the cosmetic composition according to the present invention is not particularly limited in formulation, and may be appropriately selected in accordance with the intended purpose.
- supple cosmetics skin lotion and milk lotion
- nourishing cosmetics essences
- nourishing creams massage creams
- eye creams eye essences
- packs patches
- gels sticks
- sprays cleansing creams
- cleansing products cleansing water
- It may be prepared in a formulation such as a pack, powder body lotion, body cream, body oil or body essence, but is not limited thereto.
- the composition may be used in the face, especially around the eyes, around the mouth, cheeks, forehead, neck, hands or feet, but is not limited thereto.
- White Lucent (Shiseido, Japan) was purchased and prepared.
- the main raw materials of white lucent are summarized in Table 1.
- Estra Rijedom Rx (Amorepacific, Korea).
- the main raw materials of Ezedum Rx are listed in Table 2.
- Example 52 of Korean Patent Registration No. 10-0251813 was prepared.
- the main raw materials and their contents are summarized in Table 3.
- Examples 1-10 were prepared with the compositions shown in Table 4 below, and the formulations of Examples 1-15 were prepared with the compositions shown in Table 5 below.
- Example 1 to Example 15 The preparation method of the formulation is summarized in Table 6 below. Table 6
- Skin permeability of tranexamic acid from the external preparation composition through human cadarver skin was measured using Franz Diffusion Cell.
- the Receptor was charged in a Franz Diffusion Cell and the temperature was maintained at 32 0 C and stirred at 600 rpm.
- the content of tranexamic acid in the standard solution and the sample solution was analyzed according to the following liquid chromatograph method. Then, the peak area was obtained to prepare a calibration curve of the standard solution, and the skin permeation amount was calculated therefrom. 1-4. Test equipment
- Mobile phase ll.Og of anhydrous sodium dihydrogen phosphate was dissolved in 500m of water, and 5m £ of triethylamine and 1.4g of sodium lauryl sulfate were added thereto. Adjust pH to pH4.0 with phosphoric acid and add 600m water. 400 I of methane was added to this solution.
- Tranexamic acid lOnig was dissolved in the receptor solution and diluted with the receptor solution to prepare a standard solution. (5, 20, 35, 50, 65ig / m ⁇ )
- Example 3 did not cause transdermal permeation at all regardless of time, but the formulations of the Examples showed high transdermal permeability, and the transdermal permeability continued to increase over time.
- the topical test criteria skin irritation test is applied 24 hours after applying the test substance and washed lightly with a solvent that does not affect the test results such as physiological saline so that the test substance does not remain. After 48 and 72 hours, changes in hemorrhage, edema bleeding, and skin formation were observed.
- Table 12 According to the above evaluation criteria, the results of evaluating the usability of the formulations of Examples 4, 8, 10-15 and the formulations of Comparative Examples 1, 2, and 3 are summarized in Table 13 below.
- Test substance (vehicle, Examples 4, 8, 10-12) was applied to the induced artificial pigment plate once a day, 5 days a week for 30 weeks at a rate of 30 / £. Mexameter once a week after treatment of the test substance.
- the melanin index (Skin melasma index) was measured and compared (mean value was measured by repeating the same site three times).
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480018396.0A CN105263486A (zh) | 2013-04-04 | 2014-03-28 | 改善了皮肤渗透的外用剂组合物 |
JP2016505407A JP2016515572A (ja) | 2013-04-04 | 2014-03-28 | 皮膚透過が改善された外用剤組成物 |
US14/779,927 US10292955B2 (en) | 2013-04-04 | 2014-03-28 | Composition for external use preparation with improved transdermal permeability |
CA2908041A CA2908041C (en) | 2013-04-04 | 2014-03-28 | Composition for external use preparation with improved transdermal permeability |
BR112015024623A BR112015024623A2 (pt) | 2013-04-04 | 2014-03-28 | composição para preparação de uso externo com permeabilidade transdérmica melhorada |
MX2015013727A MX2015013727A (es) | 2013-04-04 | 2014-03-28 | Composicion para preparacion de uso externo con permeabilidad transdermica mejorada. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0036912 | 2013-04-04 | ||
KR20130036912 | 2013-04-04 | ||
KR1020140036904A KR101564434B1 (ko) | 2013-04-04 | 2014-03-28 | 피부투과가 개선된 외용제 조성물 |
KR10-2014-0036904 | 2014-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163338A1 true WO2014163338A1 (ko) | 2014-10-09 |
Family
ID=51658579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002676 WO2014163338A1 (ko) | 2013-04-04 | 2014-03-28 | 피부투과가 개선된 외용제 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014163338A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10292955B2 (en) | 2013-04-04 | 2019-05-21 | Hyundai Pharm Co., Ltd. | Composition for external use preparation with improved transdermal permeability |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003160465A (ja) * | 2001-11-29 | 2003-06-03 | Shiseido Co Ltd | 経皮吸収促進用プレトリートメント剤及びそのプレトリートメント剤を用いた化粧方法 |
KR20100103830A (ko) * | 2008-01-21 | 2010-09-28 | 가부시키가이샤 시세이도 | Ⅴegfc 생성 촉진제 |
JP2010229100A (ja) * | 2009-03-27 | 2010-10-14 | Shiseido Co Ltd | 皮膚外用剤 |
KR20110046585A (ko) * | 2008-10-15 | 2011-05-04 | 가부시키가이샤 시세이도 | 피부 외용제 조성물 |
KR20120004556A (ko) * | 2009-09-17 | 2012-01-12 | 가부시키가이샤 시세이도 | 피부외용제 |
-
2014
- 2014-03-28 WO PCT/KR2014/002676 patent/WO2014163338A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003160465A (ja) * | 2001-11-29 | 2003-06-03 | Shiseido Co Ltd | 経皮吸収促進用プレトリートメント剤及びそのプレトリートメント剤を用いた化粧方法 |
KR20100103830A (ko) * | 2008-01-21 | 2010-09-28 | 가부시키가이샤 시세이도 | Ⅴegfc 생성 촉진제 |
KR20110046585A (ko) * | 2008-10-15 | 2011-05-04 | 가부시키가이샤 시세이도 | 피부 외용제 조성물 |
JP2010229100A (ja) * | 2009-03-27 | 2010-10-14 | Shiseido Co Ltd | 皮膚外用剤 |
KR20120004556A (ko) * | 2009-09-17 | 2012-01-12 | 가부시키가이샤 시세이도 | 피부외용제 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10292955B2 (en) | 2013-04-04 | 2019-05-21 | Hyundai Pharm Co., Ltd. | Composition for external use preparation with improved transdermal permeability |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10292955B2 (en) | Composition for external use preparation with improved transdermal permeability | |
AU2009331482B2 (en) | A composition comprising a retinoid and method of treating skin conditions | |
US20170087073A1 (en) | Mild leave-on skin care compositions | |
JP5572318B2 (ja) | 局所投与用アルギニンヘテロマー | |
WO2009148551A1 (en) | Cosmetic compositions | |
CA2849323A1 (en) | Hair care compositions and methods of use | |
CN109846740B (zh) | 皮肤护理组合物及其制备方法和应用 | |
EP3965724A1 (en) | Formulations and methods for preparing stable cosmetic compositions | |
WO2006068715A2 (en) | Cosmetic compositions having carnitine creatinate and methods for using | |
AU2009256524B2 (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid | |
WO2014163338A1 (ko) | 피부투과가 개선된 외용제 조성물 | |
JP2002506805A (ja) | 保湿組成物 | |
JP2005289873A (ja) | シワ改善用皮膚外用剤 | |
KR20180130178A (ko) | 리포좀 및 이를 포함하는 화장료 조성물 | |
US11020334B2 (en) | Compounds, compositions and use thereof | |
KR101626473B1 (ko) | 시클로헥산 디카르복실산 유도체를 함유하는 피부 외용제 조성물 | |
BR112016023121B1 (pt) | composição tópica | |
JP2002087928A (ja) | 化粧用保湿剤および化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480018396.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14780334 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2908041 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14779927 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016505407 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/013727 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015024623 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14780334 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112015024623 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150925 |